Zepbound Side Effects: What the Weight Loss Trials Found

    Short answer

    The most common Zepbound side effects on its FDA label are digestive: nausea, diarrhea, vomiting, constipation, stomach pain and indigestion. In the weight trials, nausea was reported by 25% to 29% of adults versus 8% on placebo, and most nausea, vomiting and diarrhea came while the dose was being raised, then decreased.

    People starting or stepping up on Zepbound want a calm, sourced picture of what to expect. The label lists nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection site reactions, fatigue, allergic reactions, burping, hair loss and reflux among the most common side effects. This page lays out how often each appeared in the weight management trials, the serious warnings, and the symptoms that need a call or emergency care. Every number comes from the Zepbound prescribing information, revised August 2026.

    The quick version

    The short version, from the Zepbound prescribing information, revised 08/2026.

    Nausea is the most reported effect

    In the two placebo-controlled weight trials, nausea was reported by 25% to 29% of adults on Zepbound compared with 8% on placebo. Diarrhea was reported by 19% to 23% and vomiting by 8% to 13%.

    More than half had a stomach effect

    Any stomach side effect was reported by 56% of people at each dose studied, compared with 30% on placebo. The label notes these can sometimes be severe, which is why it lists when to get in touch.

    Few stopped because of stomach effects

    Between 1.9% and 4.3% of people on Zepbound stopped because of stomach effects, compared with 0.5% on placebo. Those who stopped because of side effects mostly did so in the first few months.

    The label has a boxed warning

    Zepbound carries a boxed warning about thyroid C-cell tumors seen in rats. The label also lists pancreatitis, gallbladder disease, kidney injury, low blood sugar, allergic reactions and more, all covered below.

    How often each effect showed up

    The table is the label's Table 1: side effects reported by at least 2% of people on Zepbound, and more often than on placebo, in the pooled weight-reduction trials in adults with obesity or overweight. The doses in the column headings are the label's trial arms, not a recommendation.

    Side effectPlaceboZepbound 5 mgZepbound 10 mgZepbound 15 mg
    Nausea8%25%29%28%
    Diarrhea8%19%21%23%
    Vomiting2%8%11%13%
    Constipation5%17%14%11%
    Stomach pain5%9%9%10%
    Indigestion (dyspepsia)4%9%9%10%
    Injection site reactions2%6%8%8%
    Fatigue3%5%6%7%
    Allergic-type reactions3%5%5%5%
    Burping (eructation)1%4%5%5%
    Hair loss1%5%4%5%
    Reflux (GERD)2%4%4%5%
    Gas (flatulence)2%3%3%4%
    Bloating (abdominal distension)2%3%3%4%
    Dizziness2%4%5%4%
    Low blood pressure0%1%1%2%

    Nausea, vomiting and diarrhea

    Nausea was reported by 25%, 29% and 28% of people at the three doses studied, compared with 8% on placebo. Vomiting rose with the dose from 8% to 13% versus 2%, and diarrhea ranged from 19% to 23% versus 8%.

    Constipation, stomach pain and indigestion

    Constipation was reported by 11% to 17% of people on Zepbound compared with 5% on placebo. Stomach pain and indigestion were each reported by 9% to 10%, compared with 5% and 4% on placebo.

    Injection site reactions and allergic reactions

    Injection site reactions such as redness, itching or bruising were reported by 6% to 8% of people versus 2% on placebo (see GLP-1 injection site reactions). Allergic-type reactions, mostly rash and itching, were reported by 5% compared with 3%.

    Fatigue, dizziness and hair loss

    Fatigue was reported by 5% to 7% and dizziness by 4% to 5%, compared with 3% and 2% on placebo. Hair loss was linked with weight reduction and was more common in women (7.1%) than in men (0.5%).

    Burping, reflux and gas

    Burping, listed as eructation, was reported by 4% to 5% of people on Zepbound compared with 1% on placebo. Reflux, gas and bloating were each reported by 3% to 5%.

    Serious risks the label warns about

    These events are uncommon, but they are why a new or unusual symptom should not always be put down to the medicine.

    Boxed warning: thyroid C-cell tumors

    In rats, tirzepatide caused thyroid C-cell tumors, and it is unknown whether Zepbound does this in people. It should not be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with MEN 2. A lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath should be reported to your prescriber.

    Severe stomach problems and kidney injury

    The label warns that stomach side effects can be severe and that fluid loss from them can lead to acute kidney injury. In the weight trials, acute kidney injury was reported by 0.5% of people on Zepbound versus 0.2% on placebo.

    Pancreatitis and gallbladder disease

    In the weight trials, acute pancreatitis was confirmed in 0.2% of people on Zepbound and 0.2% on placebo. Gallbladder inflammation was reported by 0.7% versus 0.2%. The label lists severe stomach pain spreading to the back as a pancreatitis sign.

    Low blood pressure and low blood sugar

    Low blood pressure was reported by 1.6% of people on Zepbound compared with 0.1% on placebo, more often in those taking blood pressure medicines. In the trial of adults with type 2 diabetes, low blood sugar was reported by 4.2% versus 1.3%, and the risk rises with insulin or a sulfonylurea.

    Allergic reactions, anesthesia, pregnancy and birth control pills

    Serious allergic reactions such as anaphylaxis and angioedema have been reported, and the label lists a risk of food or liquid entering the lungs during anesthesia or deep sedation. The label says Zepbound may cause harm to an unborn baby, so tell your prescriber if you are pregnant or planning to be.

    Zepbound may make birth control pills less reliable, so the label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Talk to your prescriber about which method fits you.

    Signs that need a call or urgent care

    This list follows the warnings and Medication Guide in the Zepbound label. It is not a complete list and it is not medical advice: if something feels wrong, call.

    Go to emergency care

    Swelling of the face, lips, tongue or throat, trouble breathing, or fainting need emergency help. Severe stomach pain that will not go away, with or without vomiting, also needs urgent attention.

    Contact your prescriber

    Reach out about any of these:

    • Nausea, vomiting or diarrhea that is severe or will not go away, or signs of dehydration.
    • Dizziness or feeling faint, which can come with low blood pressure.
    • Pain in the upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be gallbladder signs.
    • Shakiness, sweating, dizziness, a fast heartbeat, hunger, headache, blurred vision, confusion or irritability, which can mean low blood sugar, especially with insulin or a sulfonylurea.
    • Any change in your vision, if you have type 2 diabetes.
    • A lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.

    Tell your surgical team

    Let your doctors know you take Zepbound before any planned surgery or procedure with anesthesia or deep sedation. The label asks for this because the stomach empties more slowly on this medicine.

    Dose and schedule questions

    Your prescriber and your label are the right sources for questions about your dose, your step-ups or a missed injection, including the label's missed-dose instructions. This page shares label facts and does not offer dosing advice.

    How to report a side effect

    The label gives two contacts for reporting a suspected side effect: Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979), or the FDA's MedWatch program at 1-800-FDA-1088.

    Why these effects happen and when they ease

    Every point here comes from the label.

    Slower stomach emptying

    The label says Zepbound delays gastric emptying, so meals stay in the stomach longer. That slower pace is tied to fullness, nausea and indigestion.

    The step-up months

    The label's schedule starts at 2.5 mg weekly for 4 weeks, with 2.5 mg increases after at least 4 weeks on a dose, as the prescriber directs. That is the label's schedule, not a plan for you: your prescriber sets yours. Most nausea, vomiting and diarrhea in the trials happened during these increases and then decreased.

    A weekly medicine that stays active

    In people with obesity, the label gives an elimination half-life of about 5 to 6 days. Because each dose lingers, some people notice their symptoms follow the same rhythm every week. The tirzepatide half-life calculator shows that curve.

    Sleep apnea trials looked similar

    Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity. In those trials, side effects were similar to the ones in the weight reduction studies.

    From the makers of this guide

    Turn rough days into a clear record

    The label gives trial averages. Your prescriber needs your version: which symptoms, how strong, and how they fall around shot day.

    1. 01

      Record what you feel and how strong it is

      The side-effect tracker has built-in GLP-1 symptoms grouped by area, such as injection site, digestive and head and nerves, plus your own, each saved by day with how severe it was. A short daily check-in asks about food noise, side effects and mood, and you can add questions such as energy and sleep.

    2. 02

      Match symptoms to shot day

      Your side-effect trend chart sits on the Dose tab beside your Zepbound shot history, so a pattern like fatigue the day after every injection, or a rough week after a step-up, is easy to point to.

    3. 03

      Check the estimated level curve

      An estimated medication-level chart on the same tab plots how your logged doses rise and fade across the week, which makes a weekly rhythm visible.

    4. 04

      Meals you can look back on

      Log meals by photo scan, barcode or search in Nutrition, then look back at harder days to spot which foods tend to sit well.

    Download on the App StoreGet it on Google Play

    Walk into your next visit prepared

    A log pays off when it reaches your prescriber.

    Export a PDF report

    Pep AI builds a PDF report of your doses, injection sites, weight and daily meal totals. Show it on your phone or send it before the appointment.

    Questions worth raising

    Ask whether your pattern is typical, what would warrant a call between visits, and how your other medicines fit in. Your prescriber decides whether anything should change.

    Stay consistent between visits

    A few taps a day keeps the record complete, and the next report is ready whenever you need it.

    Key takeaways

    • Nausea was reported by 25% to 29% of adults on Zepbound in the weight trials, versus 8% on placebo.
    • 56% had a stomach effect at every dose studied, versus 30% on placebo; most nausea, vomiting and diarrhea came during dose increases.
    • 1.9% to 4.3% stopped Zepbound because of stomach effects, versus 0.5% on placebo.
    • Zepbound carries the boxed thyroid C-cell tumor warning, and its label lists pancreatitis, gallbladder disease, kidney injury and low blood sugar.
    • Dose, step-up and missed-dose questions belong with your prescriber and your label.

    Turn rough days into a clear record.

    Pep AI logs your Zepbound shots, symptoms with severity, meals and weight, and makes a PDF of your doses, sites, weight and meal totals. Download Pep AI on iPhone or Android.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    2. MedWatch: The FDA Safety Information and Adverse Event Reporting Program

    This page summarizes the Zepbound prescribing information (revised 08/2026). It is general information, not medical advice, and does not replace your prescriber or pharmacist. Pep AI is not affiliated with or endorsed by Eli Lilly and Company. If a symptom is severe, getting worse or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026